Content
07/29/2024
Boston, MA USA
Spear Bio
completed $45 million Series A Round funding. Investors include
Foresite Capital (lead), Maverick Ventures.
About
• Spear Bio is meeting a growing market need for ultrasensitive immunoassays in smaller samples.
• Our platform, based on technology licensed from Harvard University, can detect single-digit counts of proteins per sample in minuscule sample volumes.
• Our goal is to develop high-impact immunoassays that can be easily adopted by academic and clinical researchers and practitioners.
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
